Responder Identification

Identifying patients who are likely to respond to particularly therapeutics is increasingly becoming an important element in pharmaceutical R&D. Whether for enriching clinical trials, retrospective analyses of completed clinical trials, drug/diagnostic co-development or monitoring for resistance, prediction of response together with prognosis determination and patient surveillance call for broad molecular profiling in order to detect often subtle variations which confer individual sensitivity to a pharmaceutical agent.

Predicting Response Early During Treatment
Shown below are clinical responders (green icons) and clinical non-responders (red icons), as determined at the end of a prospective clinical trial of a specific pharmaceutical agent. Panel A on the left shows the distribution of ultimate responders and non-responders based on conventional serum clinical chemistry data acquired very early during treatment. Panel B is a response prediction function index outcome based on the same serum samples early during treatment as analyzed by BG Medicine. Using analytes determined and identified by BG Medicine, ultimate clinical response to this agent can be predicted very early and with high accuracy just subsequent to treatment initiation.